TG THERAPEUTICS, INC. Proceeds from Sale of Held-to-maturity Securities
TG THERAPEUTICS, INC. (TGTX) reported Proceeds from Sale of Held-to-maturity Securities of $3.85 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities · last filed 2015-05-11
- TG THERAPEUTICS, INC. proceeds from sale of held-to-maturity securities for the quarter ending 2015-03-31 was $3.85M.
- TG THERAPEUTICS, INC. proceeds from sale of held-to-maturity securities for the quarter ending 2014-03-31 was $0.00.
| Period end | Proceeds from Sale of Held-to-maturity Securities 3 month |
|---|---|
| 2015-03-31 | $3.85M 10-Q · filed 2015-05-11 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |